Mirabella

Quick links to important sections

Mirabella

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mirabella

Quick Facts

Property Description
Active ingredient Ethinyl Estradiol and Gestodene
Form Tablet (oral)
Pharmacological class Combined Oral Contraceptive (COC); Ovulation Inhibitor
Common use Prevention of Pregnancy (Birth Control)
Origin Synthetic Hormones

What is Mirabella? Definition and Classification

Mirabella is a prescription-only medication classified as a Combined Oral Contraceptive (COC), serving the primary purpose of prevention of pregnancy. This medicine belongs to the authoritative pharmacological class of Hormonal Contraceptives and functions as a systemic Ovulation Inhibitor. The combination of hormones in this formulation is clinically recognized for its high contraceptive efficacy when used correctly. The product is designed for oral administration in the tablet dosage form, establishing its systemic delivery method for birth control.

Composition: A Combination of Synthetic Hormones

The core identity of Mirabella is defined by its two active ingredients: Ethinyl Estradiol (EE), a synthetic estrogen, and Gestodene (GSD), a synthetic progestogen. This medication is a combination product because it contains both hormone types, which are entirely synthetic in origin. Gestodene is categorized as a third-generation progestogen, meaning it possesses high potency and a unique hormonal profile compared to older progestogens. This specific formulation is a well-established standard for hormonal therapy.

High-Level Purpose: Preventing Unwanted Pregnancy

The fundamental general benefit of Mirabella is the reliable contraceptive effect achieved through its systemic antigonadotropic activity. By introducing the specific combination of hormones, the medication reliably interferes with the body’s hormonal environment, consistently preventing the key events necessary for conception. COC formulations containing Ethinyl Estradiol and a Gestodene-type progestogen offer effective fertility control for women of childbearing potential, which is the singular, defining purpose of this medicine.

What side effects are possible with Mirabella?

Possible Side Effects and Safety Information

The safety profile for Mirabella, a combination hormonal contraceptive, is documented by official regulatory bodies, focusing on the potential for serious adverse reactions and identifying specific populations for whom use is restricted.

Serious Adverse Reactions and Restrictions

The most serious documented risk involves thromboembolic events (blood clots), which are rare but potentially life-threatening. These include deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction (heart attack). Regulatory documents identify several absolute contraindications (situations where the drug must not be used) due to these risks, including a history of thromboembolic disorders, severe uncontrolled hypertension, liver tumors, or known estrogen-sensitive malignancies.

Specific population restrictions state that the use of this medicine is absolutely contraindicated in women over 35 who smoke, as this combination significantly elevates the risk of serious cardiovascular events.

Temporary discontinuation of the medicine is required before and after major surgery or during long periods of immobilization to manage the elevated risk of blood clots during these times.


Common Adverse Reactions

The most common adverse reactions reported in clinical trials (occurring in 2% of users) establish the expected, non-life-threatening side effect profile. These frequently reported reactions include headache, nausea, breast tenderness or pain, menstrual cramps (dysmenorrhea), vaginal candidiasis, bacterial vaginitis, acne, mood swings, and weight gain. These reactions are classified by frequency to indicate the baseline side effects associated with use.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Mirabella (Ethinyl Estradiol and Gestodene) indicates that acute overdosage of this combined oral contraceptive is typically associated with a low acute toxicity profile and is generally considered not likely to be life-threatening.

Documented Overdose Manifestations

The most commonly reported clinical signs following ingestion above the prescribed dose are nausea and vomiting (gastrointestinal symptoms). A physiological outcome documented in regulatory summaries is withdrawal bleeding, which may be similar to a heavy menstrual period. Headache, breast tenderness, and discolored urine are also noted.

Required Emergency Action

In the event of a suspected overdose, regulatory guidance mandates that individuals seek medical help right away. Patients must contact emergency services or a certified Poison Control Center immediately. A specific consideration exists for the accidental ingestion by children, which requires the same urgent action.

Management and Monitoring

No specific antidote is known for this hormonal combination. Therefore, management of overdosage is officially restricted to symptomatic and supportive treatment. Medical providers may monitor vital signs, and regulatory information notes the potential use of laboratory monitoring, including blood and urine tests.

Therapeutic Uses of Mirabella

The fundamental purpose of Mirabella (Ethinyl Estradiol and Gestodene) is to provide effective fertility management for women of childbearing potential, serving as a recognized method of contraception. Beyond pregnancy prevention, the hormone combination is applied across relevant domains to offer support for symptomatic relief and therapeutic benefit related to menstrual health and endocrine balance. These medications are commonly used for symptomatic relief in various menstrual and hormonal conditions.

The medicine is relevant in clinical settings that involve symptoms that interfere with daily functioning caused by the menstrual cycle and hormonal changes. It is commonly used in situations involving conditions and symptoms such as dysmenorrhea (painful periods), menorrhagia (heavy blood loss), cycle irregularity, and the symptoms associated with moderate acne vulgaris.

“It contributes to easing the overall symptom load and helps improve day-to-day comfort.”

This approach helps address symptom clusters that require supportive management, contributing to predictable cycle patterns and assisting with maintaining a sense of functional stability when symptoms interfere with routine activities.


Quick Fact: Relief for Menstrual Discomfort

Property Description
Primary Domain Fertility Management
Symptomatic Relief Painful periods (dysmenorrhea) and heavy flow (menorrhagia)
Hormonal Benefit Supports predictable cycle patterns and helps manage moderate acne
General Scenario Routine health management where cycle predictability is relevant

Regulatory References

  1. NIH Overview of Oral Contraceptive Pills

Eligibility and Restrictions for Use

Who Can and Cannot Use Mirabella?

The eligibility for Mirabella (Ethinyl Estradiol and Gestodene) is determined by strict regulatory criteria common to all Combined Oral Contraceptives (COCs), focusing on the absence of major health risks.

Contraindicated Populations

Use of Mirabella is absolutely contraindicated in several high-risk populations as defined in official labeling. This includes any female with a current or history of venous or arterial thromboembolism (e.g., DVT, PE, stroke, or MI). The medicine is also prohibited for females over age 35 who smoke.

Contraindications extend to conditions that are hormone-sensitive or affect metabolism: known or suspected breast cancer or other estrogen-dependent cancers, severe hepatic impairment, liver tumors, or uncontrolled hypertension. Furthermore, the medicine must not be used by individuals with diabetes mellitus with vascular disease or those experiencing migraine with focal neurological symptoms (aura).

Age and Physiological Restrictions

Category Regulatory Status
Pediatric Use Not established; not recommended prior to menarche.
Geriatric Use Not indicated in post-menopausal women.
Pregnancy Contraindicated.
Lactation Not recommended (may affect milk quantity/quality).

The standard approved population for Mirabella is women of reproductive potential who do not have any of the listed contraindications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Mirabella (Ethinyl Estradiol and Gestodene) interacts with various medicines and substances, with documented interaction patterns classified primarily by their effect on drug exposure and resulting prohibitions.


Formal Contraindicated Combinations

Co-administration is strictly contraindicated with specific Hepatitis C antiviral combinations due to the official risk of significant liver enzyme elevations. This includes products containing Ombitasvir / Paritaprevir / Ritonavir with Dasabuvir, or products containing Glecaprevir / Pibrentasvir or Sofosbuvir / Velpatasvir / Voxilaprevir.

Exposure-Altering Interactions

Interaction Type Interacting Substance/Class Official Regulatory Outcome
Exposure Decrease Hepatic Enzyme Inducing Drugs (e.g., Rifampin, Griseofulvin, St. John's Wort) Decreased plasma concentrations of active hormones.
Exposure Increase CYP3A4 Inhibitors (Class), Etoricoxib Increased systemic exposure of the Ethinyl Estradiol component.

Pharmacodynamic Effects

Co-administration with non-aspirin Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may be associated with an officially documented potential for an increased risk of Venous Thromboembolism (VTE). Additionally, Mirabella may inhibit the metabolic clearance of other drugs, such as Tizanidine, leading to significantly increased plasma concentrations of the co-administered drug.

Mechanism of Action

Targeting Beta-3 Adrenergic Receptors

Mirabella acts within the domain of receptor-mediated signaling by functioning as a highly selective agonist of the human beta3-adrenergic receptor (beta3-AR). These receptors are predominantly located on the detrusor smooth muscle, which comprises the wall of the urinary bladder. This targeted engagement initiates the drug's mechanism of action by binding to and activating the receptor structure.


Modulation of Smooth Muscle Relaxation

Activation of the beta3-AR initiates a mechanistic cascade involving the activation of adenylyl cyclase. This enzyme increases the intracellular concentration of cyclic adenosine monophosphate (cAMP). The subsequent elevation of cAMP levels promotes the relaxation of the detrusor muscle tissue, primarily during the storage phase. This modification of cellular signaling results in a change in detrusor muscle tone, representing the system-level physiological modulation of the drug.

Dosage and Administration Information

How to use Mirabella

Mirabella, a Combined Oral Contraceptive (COC) containing Gestodene and Ethinyl Estradiol, is administered exclusively as a film-coated tablet following a specific daily, cyclic schedule.

Administration Protocol

Parameter Instruction
Route of Administration The tablet must be taken orally (by mouth) only.
Standard Dosing Schedule Take one tablet daily at approximately the same time every day to maintain steady hormone levels.
Dosing Cycle Use follows a 28-day regimen, typically consisting of 21 active tablets (e.g., 75 mcg Gestodene/30 mcg Ethinyl Estradiol) followed by a 7-day tablet-free or inactive tablet interval. Other regimens, such as a 24/4 day schedule, are also utilized.
Administration Order Tablets must be taken in the sequential order directed on the blister pack packaging.
Relation to Meals The tablet may be taken with or without food.

Procedural Requirements and Use Constraints

Starting Use: Initiation of the first pack should typically begin on the first day of the menstrual period (Day 1 Start) or on the first Sunday following the start of the period (Sunday Start). Starting after Day 1 may require the use of a non-hormonal barrier method for the first seven days of active tablet use.

Missed Dose Instructions: Adherence to the scheduled time is critical. If a dose is missed by less than 12 hours, the tablet should be taken immediately, and the regular schedule continued. If the tablet is missed by more than 12 hours, contraceptive protection may be compromised, and a non-hormonal barrier method must be used for the subsequent seven days of continuous active tablet use.

These instructions define a continuous, sequential use protocol where strict daily compliance, adherence to the tablet order, and precise action for a missed dose are the primary requirements for proper usage.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mirabella


Evidence for use in Preventing Pregnancy (Contraception)

Research examined how Mirabella was studied for its primary use in Randomized Controlled Trials (RCTs) and various long-term clinical trials. Researchers examined whether ovulation inhibition occurred and what changes were monitored in the hormonal environment. These studies monitored the rate of pregnancy among healthy women of childbearing potential over extended periods, often following them for up to three years. The findings describe patterns observed where the occurrence of pregnancy was measured in clinical trial settings. Long-term data extending up to three years reported patterns in cycle control and the incidence of unscheduled bleeding.


Evidence for Managing Symptomatic Relief Related to the Menstrual Cycle

Mirabella was evaluated in studies exploring symptoms, including the design of studies that examined outcomes related to painful periods (dysmenorrhea) and heavy blood loss (menorrhagia). Studies examined patient-reported outcomes describing perceived discomfort and outcomes related to physical discomfort. These studies report how symptoms evolved in the observed populations, with findings describing patterns of change in the duration and intensity of menstrual blood loss and the reported severity of pain.

Research exploring outcomes related to Moderate Acne Vulgaris

Research on acne was observed in Randomized Controlled Trials (RCTs), where this specific formulation was evaluated in female subjects with moderate facial acne. Research examined changes in the severity of acne lesions, the total number of lesions, and shifts in specific systemic or functional imbalance markers related to hormones. Trials reported changes measured during the study period in the counting of acne lesions and in biochemical markers.


What Remains Uncertain and Areas for Further Research

Research highlights what is known—and what is still uncertain—in the broader evidence landscape for Mirabella. Certainty remains low on the long-term effects of the medicine on all outcomes reflecting daily functioning beyond three years, as most pivotal trials conclude around this mark. Key evidence gaps were observed in some studies, particularly regarding the lack of uniformity in direct comparative evidence when measuring the difference between this formulation and other low-dose contraceptive options. Study results reflect the specific conditions under which they were conducted and do not determine whether an individual will respond similarly.

Key Studies & References

  1. Oral Contraceptive Pills (StatPearls - NIH, used for general mechanism and adherence context)

Frequently Asked Questions (FAQ)

Common questions about Mirabella (FAQ)

Q: Is it normal to feel tired or dizzy when first starting Mirabella?

Official product information notes that certain non-serious effects are commonly reported when using this class of medicine. These reactions can include headache, nausea, mood changes, and breast tenderness. Dizziness and feeling tired are also documented as possible side effects.


Q: What types of over-the-counter medicines should be checked for interactions with Mirabella?

Interactions are described with medicines that affect liver enzymes, which can change how the body processes Mirabella. Checking with a healthcare provider about any over-the-counter products, especially herbal ingredients like St. John's Wort, is recommended. Certain products may decrease the amount of hormones in the medicine, affecting its primary purpose.


Q: Are there any known long-term effects from using Mirabella for many years?

Regulatory documents describe that prolonged use of combined oral contraceptives is associated with a rare but serious risk of thromboembolic disorders (blood clots). Long-term use is also linked to the potential for increased risk of liver tumors and gallbladder disease. Official guidance highlights that certainty remains low for outcomes beyond three years of use.


Q: Can Mirabella cause stomach upset or digestive issues?

Official regulatory documents list several common gastrointestinal adverse reactions. These frequently reported issues can include nausea and vomiting. Stomach pain or cramping is also reported by some users.


Q: What is the usual expectation for the duration of treatment with Mirabella?

Mirabella is indicated for continuous, cyclic use for pregnancy prevention in women of reproductive potential. The official intent is for the medicine to be used as long as contraception is desired and the patient remains free of any contraindications or health risks described in the labeling.


Q: Can the Mirabella tablet be split or crushed?

Mirabella is provided as a film-coated tablet intended to be swallowed whole. The regulatory instructions advise against splitting, crushing, or chewing the tablet. Altering the pill can affect the way the medicine is absorbed by the body, which could compromise its contraceptive efficacy.


Q: How long does it typically take for Mirabella to start working?

According to the official product information, contraceptive protection is generally established after 7 consecutive days of taking the active tablets. Therefore, a non-hormonal back-up method is generally recommended during the first seven days of the first pack.


Q: Do the side effects of Mirabella usually lessen or go away over time?

Official documents note that adjustment can take time for hormonal contraceptives. Common effects, such as irregular bleeding, are frequently seen during the initial cycles (like the first three months). These effects may gradually lessen or resolve over time, as described in studies.


Q: Does Mirabella interact with alcohol consumption?

Official information suggests a minor interaction with alcohol (ethanol). Due to the drug’s potential effect on the liver, caution is described. Users may consider avoiding or limiting alcohol consumption while using this medicine.


Q: Where can I find the official prescribing information for Mirabella?

The full official prescribing information is publicly maintained by government regulatory bodies such as the FDA or the EMA. This information is typically found on their websites by searching for the medicine's trade name or the active ingredients, Ethinyl Estradiol and Gestodene.


Q: Can Mirabella affect a person's ability to drive or operate machinery?

Based on regulatory safety advice, the use of Mirabella does not typically affect a person's ability to drive or safely use machinery. However, if any side effects such as dizziness or tiredness are experienced, caution is generally advised.


Q: Can Mirabella affect sleep patterns, such as causing insomnia?

Regulatory documents for this class of medicine indicate that trouble sleeping or insomnia is listed as a possible adverse reaction. This is described as an effect on the central nervous system that may occur in some users.


Q: Is it true that Mirabella interacts with grapefruit or grapefruit juice?

Official regulatory information describes the potential for interaction regarding the consumption of grapefruit or grapefruit juice. These products can affect an enzyme in the body that processes the medicine, which may increase the concentration of the hormones and potentially raise the risk of side effects.


Q: Are there any specific lab tests or monitoring required while on Mirabella?

Regulatory guidance recommends regular medical check-ups. Monitoring may include checking blood pressure, as well as checking lipid profiles (fats in the blood) and liver function, particularly for patients with pre-existing conditions.


Q: What is the difference between the various available strengths of Mirabella?

The difference between the available strengths lies in the quantity (dosage) of the active hormonal ingredients. This formulation contains varying amounts of Ethinyl Estradiol and Gestodene. The appropriate strength is determined by regulatory-approved prescribing criteria.

How should Mirabella be stored and disposed of?

How to Store and Dispose of Mirabella?

The storage and disposal of Mirabella (Ethinyl Estradiol and Gestodene) must adhere strictly to official regulatory requirements to ensure product stability and environmental protection.

Official Storage Requirements

Condition Requirement
Temperature Store at a temperature that does not exceed 25°C.
Container Must be kept in the original blister pack to protect the tablets from light and moisture.
Safety Keep the medicine out of the sight and reach of children.

Official Disposal Instructions

To comply with environmental protection mandates, unused or expired Mirabella must not be disposed of in household rubbish or via wastewater (e.g., toilet or sink). Disposal must involve returning the product to a pharmacist or a local authority's designated collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mirabella found in:

A-Z Index: